Experts in TLR Biology

We are developing cutting edge immunotherapies based on Toll-Like Receptor (TLR) biology and its ability to modulate the immune system. Learn More >

Cancer Immunotherapy

Through our expertise in TLR biology we have designed compounds that stimulate multiple innate mechanisms of tumor killing and development of immune memory associated with tumor-specific antigens. Learn More >

‹ ›

HEPLISAV-B™

HEPLISAV-B is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with a proprietary TLR9 agonist to enhance the immune response. HEPLISAV-B is currently in Phase 3 clinical trials.

Learn More ›

Toll-like Receptor (TLR) Platform

Our TLR platform is broadly applicable across multiple diseases including infectious diseases, cancer and asthma.

Learn More ›

News

Jan12

Dynavax to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Dec29

Dynavax Secures $40 Million Credit Facility With Hercules Technology Growth Capital

Dec09

Dynavax Announces Webcast of R&D Day

View All News

Our values

At Dynavax we are proud of work we do. Our corporate values provide the foundation of our culture and how we operate as a company.

Learn More ›